Literature DB >> 28392314

Persistence and proliferation of human mesenchymal stromal cells in the right ventricular myocardium after intracoronary injection in a large animal model of pulmonary hypertension.

Roza Badr Eslam1, Kevin Croce2, Fernanda Marinho Mangione2, Robert Musmann2, Jane A Leopold2, Richard N Mitchell3, Aaron B Waxman4.   

Abstract

BACKGROUND AIMS: In this study, we demonstrate long-term persistence of human mesenchymal stromal cells (hMSCs) after intracoronary injection in a large animal model of pulmonary hypertension (PH).
METHODS: Commercially available placenta-derived hMSCs were used. Experiments were conducted on 14 female Yorkshire swine. Four animals served as controls, and 10 underwent pulmonary vein (PV) banding. After 12 ± 2 weeks, PH and PV dysfunction were confirmed by right heart catheterization and cardiac magnetic resonance imaging. hMSCs were injected in the marginal branch of the right coronary artery. Tissues were harvested 6, 9 or 24 days after infusion.
RESULTS: After 12 ± 2 weeks after PV banding, all subjects had increased mean pulmonary artery pressure (13.6 ± 3.6 versus 30.8 ± 4.5 mm Hg, P < 0.007) and a decrease in right ventricular ejection fraction from 51.7 ± 5.7% versus 30.5 ± 11.3% (P = 0.003). Intracoronary injection of hMSCs was well tolerated. Up to 24 days after hMSC injection, immunohistochemistry revealed extravascular viable human CD105+ mononuclear cells in the right ventricle (RV) that were Ki67+. This was confirmed by fluorescence in situ hybridization. CD45+ porcine inflammatory cells were identified, commonly seen adjacent to areas of healing microscopic infarction that likely dated to the time of the original hMSC injection. Anti-CD31 staining produced strong signals in areas of injected hMSCs. Immunohistochemistry staining for vascular cell adhesion molecule-1 showed upregulation in the clusters, where mononuclear cells were located.
CONCLUSIONS: hMSCs injected via intracoronary infusion survived up to 24 days and demonstrated proliferative capacity. hMSCs can persist long term in the RV and are potential cell source for tissue repair in RV dysfunction.
Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  differentiation; human mesenchymal stromal cells; intracoronary injection; pulmonary hypertension; right ventricular remodeling

Mesh:

Substances:

Year:  2017        PMID: 28392314      PMCID: PMC5502690          DOI: 10.1016/j.jcyt.2017.03.002

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  33 in total

1.  Expression of the endothelial markers PECAM-1, vWf, and CD34 in vivo and in vitro.

Authors:  Annette M Müller; M Iris Hermanns; Carmen Skrzynski; Maya Nesslinger; Klaus-Michael Müller; C James Kirkpatrick
Journal:  Exp Mol Pathol       Date:  2002-06       Impact factor: 3.362

2.  Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart.

Authors:  Georgina M Ellison; Daniele Torella; Santo Dellegrottaglie; Claudia Perez-Martinez; Armando Perez de Prado; Carla Vicinanza; Saranya Purushothaman; Valentina Galuppo; Claudio Iaconetti; Cheryl D Waring; Andrew Smith; Michele Torella; Carlos Cuellas Ramon; Jose Manuel Gonzalo-Orden; Valter Agosti; Ciro Indolfi; Manuel Galiñanes; Felipe Fernandez-Vazquez; Bernardo Nadal-Ginard
Journal:  J Am Coll Cardiol       Date:  2011-06-30       Impact factor: 24.094

Review 3.  Mesenchymal stem cells: immune evasive, not immune privileged.

Authors:  James A Ankrum; Joon Faii Ong; Jeffrey M Karp
Journal:  Nat Biotechnol       Date:  2014-02-23       Impact factor: 54.908

4.  Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation.

Authors:  Chang Dong Li; Wei Yuan Zhang; He Lian Li; Xiao Xia Jiang; Yi Zhang; Pei Hsien Tang; Ning Mao
Journal:  Cell Res       Date:  2005-07       Impact factor: 25.617

Review 5.  Immunomodulatory effect of mesenchymal stem cells.

Authors:  C Herrero; J A Pérez-Simón
Journal:  Braz J Med Biol Res       Date:  2010-04-23       Impact factor: 2.590

6.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

7.  Increased cardiomyocyte differentiation from human embryonic stem cells in serum-free cultures.

Authors:  Robert Passier; Dorien Ward-van Oostwaard; Jolanda Snapper; Jantine Kloots; Rutger J Hassink; Ewart Kuijk; Bernard Roelen; Aart Brutel de la Riviere; Christine Mummery
Journal:  Stem Cells       Date:  2005 Jun-Jul       Impact factor: 6.277

Review 8.  Mesenchymal stem cells and their potential as cardiac therapeutics.

Authors:  Mark F Pittenger; Bradley J Martin
Journal:  Circ Res       Date:  2004-07-09       Impact factor: 17.367

Review 9.  Stem cell-related therapies for vascular diseases.

Authors:  E Martin-Rendon; J A Snowden; S M Watt
Journal:  Transfus Med       Date:  2009-08       Impact factor: 2.019

10.  Placental mesenchymal stem cells of fetal and maternal origins demonstrate different therapeutic potentials.

Authors:  Yongzhao Zhu; Yinxue Yang; Yaolin Zhang; Guiliang Hao; Ting Liu; Libin Wang; Tingting Yang; Qiong Wang; Guangyi Zhang; Jun Wei; Yukui Li
Journal:  Stem Cell Res Ther       Date:  2014-04-10       Impact factor: 6.832

View more
  2 in total

1.  Wnt/β-Catenin Participates in the Repair of Acute Respiratory Distress Syndrome-Associated Early Pulmonary Fibrosis via Mesenchymal Stem Cell Microvesicles.

Authors:  Xingcai Zhang; Lifang Ye; Wan Tang; Yiqin Ji; Li Zheng; Yijun Chen; Qidong Ge; Changshun Huang
Journal:  Drug Des Devel Ther       Date:  2022-01-19       Impact factor: 4.162

Review 2.  Effects of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Future Perspectives.

Authors:  Haiyan Guo; Yue Su; Fang Deng
Journal:  Stem Cell Rev Rep       Date:  2020-11-19       Impact factor: 5.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.